AbbVie Inc. (LON:0QCV)

Market Cap	282.20B
Revenue (ttm)	45.00B
Net Income (ttm)	3.39B
Shares Out	n/a
EPS (ttm)	1.91
PE Ratio	83.36
Forward PE	n/a
Dividend	4.96 (2.52%)
Ex-Dividend Date	Apr 15, 2025

Volume	2,192
Average Volume	30,720
Open	196.00
Previous Close	196.18
Day's Range	195.86 - 198.00
52-Week Range	131.22 - 167.80
Beta	0.56
RSI	78.93
Earnings Date	Jan 31, 2025

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Employees: 55,000
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QCV

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD